NCT06342427COMPLETEDanonymous

Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA

Sponsor

Source record

City of Hope Medical Center

Phase

Source record

Not classified

Modality

AI-normalized

RNA therapy

Target

AI-normalized

DESTINEX

Indication / condition

AI-normalized

Gastric Cancer

Intervention

Source record

DESTINEX

Related intelligence directories

Indication directory: Gastric Cancer Modality directory: RNA therapy Target directory: DESTINEX

Source & freshness

Source record

NCT ID

NCT06342427

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jun 22, 2026

Internal sync

Jun 22, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT06342427

Title

Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA

Sponsor

City of Hope Medical Center

Status

COMPLETED

Phase

Detailed source ingestion pending

Condition raw

Gastric Cancer, Gastric Adenocarcinoma, Gastric Cancer Stage, Gastric Neoplasm, Gastric Lesion, Gastric Cancer in Situ, Gastric Cancer Stage IV, Gastric Cancer Stage IIIB, Gastric Cancer Stage III, Gastric Cancer Stage IB, Gastric Cancer Stage IA, Gastric Cancer, Stage 0, Gastric Cancer Stage IIIA, Gastric Cancer Stage II, Gastric Cancer TNM Staging, Gastric Cancer Metastatic to Lung, Gastric Cancer Metastatic to Liver, Gastric Cancer Stage I, Gastric Cancer TNM Staging Primary Tumor (T) T2B

Condition normalized

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

DESTINEX

Target normalized

DESTINEX

Interventions

DESTINEX

Public preview

Source record

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 24, 2026

Report code

NCT06342427-Jun 24, 2026

NCT ID

NCT06342427

Status

COMPLETED

Phase

N/A

Sponsor

City of Hope Medical Center

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJun 22, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06342427

Indication

Gastric Cancer

Modality

RNA therapy

Target

DESTINEX

Intervention

DESTINEX

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.